Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Chen, Gang ^a   He, Cheng ^a   Li, Ling ^a   Lin, An ^a   Zheng, Xiongwei ^a   He, Ellen ^b   Skog, Sven ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Sino Swed Molecular Bio Medicine Research Institute   (China)

Author keywords

Cervical intraepithelial neoplasia (CIN); Cervical lesions; Invasive cervical carcinoma; Ki 67; TK1

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; NUCLEAR PROTEIN; THYMIDINE KINASE 1; THYMIDINE KINASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ELECTROSURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRECANCER; PREDICTION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERUS SURGERY; BIOSYNTHESIS; CELL NUCLEUS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84877879929     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-249     Document Type: Article

References (25)

1. Imesch P, Fink D. Cervical cancer Ther Umsch 2011, 68:545-552.
2. Cheung FY, Mang OW, Law SC. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong 1997-2006. Hong Kong Med J 2011, 17:89-95.
3. Underwood JCE. General and systematic pathology 2005, London: Churchill Livingstone.
4. Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R, Hildenbrand R. A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31,000 women in West Germany. Eur J Cancer Prev 2009, 18:307-315. 10.1097/CEJ.0b013e328324061a, 19436214.
5. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88. 10.1016/S1470-2045(11)70296-0, 22177579.
6. Isacson C, Kessis TD, Hedrick L, Cho KR. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996, 56:669-674.
7. Kruse AJ, Baak JP, Janssen EA, Kjellevold KH, Fiane B, Lovslett K, Bergh J, Robboy S. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004, 26:13-20.
8. Queiroz C, Silva TC, Alves VA, Villa LL, Costa MC, Travassos AG, Filho JB, Studart E, Cheto T, de Freitas LA. Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. Pathol Res Pract 2006, 202:731-737. 10.1016/j.prp.2006.07.003, 16979303.
9. Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S, Kim JW. Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 2008, 19:162-168. 10.3802/jgo.2008.19.3.162, 2676462, 19471565.
10. Gertych A, Joseph AO, Walts AE, Bose S. Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based pap tests for improved cervical cancer risk stratification. Ann Biomed Eng 2012, 40:1192-1204. 10.1007/s10439-011-0498-8, 3336006, 22215277.
11. Gasparri F, Wang N, Skog S, Galvani A, Eriksson S. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol 2009, 88:779-785. 10.1016/j.ejcb.2009.06.005, 19726104.
12. Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W, Skog S. Thymidine kinase 1 expression is significantly different in breast benign (UDH), and in pre-malignant (ADH), primary tumour in situ (DCIS) and invasive ductal (IDC) of breast carcinoma. Mol Med Rep 2009, 2:923-929.
13. Ye FP, Xie QL, Liu XL, Zeng JH, Nan JL, Yu M. Expression of TK1 and Ki67 in prostate diseases. J Clin Exp Pathol 2008, 24:644-667.
14. Aufderklamm S, Hennenlotter J, Todenhoefer T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J, Merseburger A, Gerber V, Ordelheide A, Hevler J, Stenzl A, Schwentner C. XPA-210: a new proliferation marker determines locally dvanced prostate cancer and is a predictor of biochemical recurrence. World J Urol 2011, 4:21969130. PMID.
15. Liu C, Gao Q, Shi QL, Yu B, Ma HH, Eriksson S, He E, Skog S. Significance of TK1 and Ki-67 expression in ovarian serous adenocarcinoma. J Clin Exp Pathol 2011, 27:1289-1293.
16. Kruck S, Hennenlotter J, Vogel U, Schilling D, Gakis G, Hevler J, Kuehs U, Stenzl A, Schwentner C. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU Int 2012, 109:634-638. 10.1111/j.1464-410X.2011.10392.x, 21711439.
17. Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B, Zhou X, Eriksson S, He E, Skog S. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumor Biol 2012, 33:475-483.
18. Gakis G, Hennenlotter J, Scharpf M, Hevler J, Schilling D, Kuehs U, Stenzl A, Schwentner C. XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol 2011, 29:801-806. 10.1007/s00345-010-0621-8, 21113600.
19. Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C. Thymidine kinase and cancer monitoring. Cancer Lett 2012, 6:6-10.
20. Topolcan O, Holubec L. The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2008, 2:129-141. 10.1517/17530059.2.2.129, 23485133.
21. He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL, Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids 2010, 29:352-358. 10.1080/15257771003738535, 20544519.
22. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000, 70:209-262.
23. Sobin LH, Wittekind C. International Union against Cancer (UICC) TNM Classification of Malignant Tumours 6th edition 2002, New Jersey: John Wiley & Sons.
24. He Q, Wang N, Skog S, Ericsson S, Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Europ J Cell Biol 1996, 70:117-124.
25. Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution thymidine kinase 1 in repair of DNA damage. J Biol Chem 2010, 285:27327-27335. 10.1074/jbc.M110.137042, 2930731, 20554529.